PHAR - MCAP CO - Pharming Group N.V.

Pharming Group N.V. (PHAR) specializes in the therapy of rare immune pathologies, utilizing innovative molecule extraction from genetically modified rabbit milk, which renders Ruconest a high-margin product. The price action on this chart, which currently stands at 0.74, links this success to a model of fully delegating production and trials to external partners. Simultaneously, the business minimizes dependency risks associated with CMO plants through long-term agreements and digital logistics.

Market capitalization aggregates current asset demand, reflecting the total value of all issued shares through the lens of market expectations. The market value dynamics of all Pharming Group N.V. (PHAR) shares allow for an assessment of the premium investors are willing to pay for ownership of a unique recombinant protein production complex, given the stability of product supplies from high-tech laboratories in the Netherlands.